Patents by Inventor Nicolas Poirier

Nicolas Poirier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12371502
    Abstract: The invention relates to antibodies directed against CD127, the alpha chain of the interleukin 7 (IL-7) receptor IL-7R), and which have antagonist properties for IL-7-IL-7R interaction, may present cytotoxic activity against CD127 positive cells but do not increase the maturation of dendritic cells (DCs) induced by TSLP, a cytokine also using CD127 as part of its receptor. Alternatively, or in addition, these antibodies do not induce the internalization of CD127 and/or inhibit the IL7-induced internalization of CD127.
    Type: Grant
    Filed: September 9, 2022
    Date of Patent: July 29, 2025
    Assignee: OSE IMMUNOTHERAPEUTICS
    Inventors: Nicolas Poirier, Caroline Mary, Bernard Vanhove
  • Publication number: 20250215108
    Abstract: The present invention provides new anti-SIRPa antibodies able to specifically antagonize the interaction between SIRPa and CD47, without affecting the interaction between SIRPg and CD47, and their uses.
    Type: Application
    Filed: March 11, 2025
    Publication date: July 3, 2025
    Inventors: Nicolas POIRIER, Caroline MARY, Bernard VANHOVE, Vanessa GAUTTIER, Virginie THEPENIER, Sabrina PENGAM
  • Patent number: 12331115
    Abstract: The invention pertains to the field of immunotherapy. The present invention provides new uses of anti-SIRPg antibodies for the treatment and/or the prevention of autoimmune disorders or diseases.
    Type: Grant
    Filed: January 9, 2022
    Date of Patent: June 17, 2025
    Assignee: Ose Immunotherapeutics
    Inventors: Nicolas Poirier, Caroline Mary, Vanessa Gauttier, Virginie Thepenier, Sabrina Pengam, Bernard Vanhove
  • Patent number: 12335349
    Abstract: The present specification provides, amongst other things, a computing network computing optimization and method that can select and generate a digital redirect token for association with content that includes a proposed travel schema with an affiliation with the content.
    Type: Grant
    Filed: August 4, 2023
    Date of Patent: June 17, 2025
    Assignee: AMADEUS S.A.S.
    Inventors: Hervé Prezet, Massimiliano Maini, Rodolphe Texier, Nicolas Poirier
  • Patent number: 12331118
    Abstract: Described herein are humanized anti-PD-1 antibodies, nucleic acids encoding such, and uses thereof in enhancing immune responses by activating T cells and treating diseases such as cancer and an infectious disease.
    Type: Grant
    Filed: June 2, 2022
    Date of Patent: June 17, 2025
    Assignee: OSE IMMUNOTHERAPEUTICS
    Inventors: Nicolas Poirier, Caroline Mary, Virginie Thepenier, Aurore Morello, Sabrina Pengam
  • Publication number: 20250171391
    Abstract: Disclosed herein is a process for preparing a compound of formula (I). Also disclosed herein are compounds of formula (V), formula (VI), and formula (VIII).
    Type: Application
    Filed: February 15, 2023
    Publication date: May 29, 2025
    Inventors: Oliver KNOPFF, Nicolas POIRIER, Murielle HALDIMANN SANCHEZ, Virginie BLANCHARD
  • Publication number: 20250171390
    Abstract: Disclosed herein is a process for preparing a compound of formula (I) starting from a compound of formula (II). Also disclosed herein are a process to prepare a compound of formula (II) and the compound of formula (II).
    Type: Application
    Filed: March 1, 2023
    Publication date: May 29, 2025
    Inventors: Oliver KNOPFF, Jean-Jacques RIEDHAUSER, Nicolas POIRIER, Luigi MARINONI
  • Publication number: 20250154090
    Abstract: Described herein is a process for preparing a compound of formula (I). A compound of formula (III), a compound of formula (IV) and a compound of formula (V) are also described herein.
    Type: Application
    Filed: March 1, 2023
    Publication date: May 15, 2025
    Inventors: Oliver KNOPFF, Jean-Jacques RIEDHAUSER, Nicolas POIRIER, Luigi MARINONI
  • Patent number: 12258577
    Abstract: The invention relates to methods and preparations for sorting out T effector cells from human leukocytes using anti-CD127 antibodies. Accordingly the invention relates to the use of anti-CD127 antibodies enabling discriminative depletion of subpopulations of Tregulatory cells expressing CD127+ at low levels in a population of human T lymphocytes in order to enable the use of the recovered selected cell preparations comprising essentially Teffector cells as lymphocytes and preferably devoid of Tregulatory cells, for improved efficacy in particular when administered to a patient for therapy.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: March 25, 2025
    Assignees: Ose Immunotherapeutics, Etablissement Francais Du Sang, Assistance Publique—Hopitaux De Paris
    Inventors: Bernard Vanhove, Nicolas Poirier, Sebastien Maury, Jose Cohen, Caroline Pilon, Brigitte Birebent
  • Patent number: 12252546
    Abstract: The present invention provides new anti-SIRPa antibodies able to specifically antagonize the interaction between SIRPa and CD47, without affecting the interaction between SIRPg and CD47, and their uses.
    Type: Grant
    Filed: February 25, 2022
    Date of Patent: March 18, 2025
    Assignee: OSE IMMUNOTHERAPEUTICS
    Inventors: Nicolas Poirier, Caroline Mary, Bernard Vanhove, Vanessa Gauttier, Virginie Thepenier, Sabrina Pengam
  • Publication number: 20250047755
    Abstract: The present specification provides, amongst other things, a computing network computing optimization and method that can select and generate a digital redirect token for association with content that includes a proposed travel schema with an affiliation with the content.
    Type: Application
    Filed: August 4, 2023
    Publication date: February 6, 2025
    Inventors: Hervé Prezet, Massimiliano Maini, Rodolphe Texier, Nicolas Poirier
  • Publication number: 20250026839
    Abstract: The invention relates to the use of compounds that reduce the signaling pathway induced by CLEC-1/TRIM21 interaction, in particular compounds that antagonize the interaction, in particular the binding between CLEC-1 and TRIM21, the use of the identified ligand TRIM21 for designing treatment in a patient, in the identification of cells susceptible to interact with cells expressing CLEC-1, and their uses in therapy.
    Type: Application
    Filed: November 9, 2022
    Publication date: January 23, 2025
    Inventors: Vanessa Gauttier, Caroline Mary, Nicolas Poirier, Emmanuelle Wilhelm, Géraldine Teppaz, Elise Chiffoleau
  • Publication number: 20240400695
    Abstract: The present invention relates to methods for promoting T cells response. The inventors examined the expression and function of CLEC-1 in human DCs and demonstrated for the first time a cell-surface expression. They investigated its functional role following triggering on orchestration of T-cell responses. The inventors showed in vitro and in vivo with CLEC-1 deficient rats and rat CLEC-1 Fc fusion protein that disruption of CLEC-1 signalling enhances in vitro Th17 activation and in vivo enhances T cell priming and Th17 and Th1 activation. In particular, the present invention relates to CLEC-1 antagonists for promoting T cells response in a subject in need thereof.
    Type: Application
    Filed: August 21, 2024
    Publication date: December 5, 2024
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE NANTES, OSE IMMUNOTHERAPEUTICS
    Inventors: Elise CHIFFOLEAU, Geraldine TEPPAZ, Nicolas POIRIER, Bernard VANHOVE, Vanessa GAUTTIER
  • Publication number: 20240384349
    Abstract: The invention relates to the identification of biomarkers of the response status of a patient for a treatment with anti-TNFalpha agents, for treatment with anti-?4?7 agents or with both anti-TNFalpha agent and anti-?4?7 agents and to their use in assessing such status, in particular for assessing nonresponsive status for a treatment with anti-TNFalpha agents or respectively with anti-?4?7 agent in human patients suffering from inflammatory condition or disease, in particular Inflammatory Bowel Disease (IBD), in particular Ulcerative Colitis or Crohn's disease.
    Type: Application
    Filed: July 30, 2024
    Publication date: November 21, 2024
    Inventors: Nicolas POIRIER, Richard DANGER
  • Publication number: 20240368068
    Abstract: The present invention relates to the field of perfumery. More particularly, it concerns valuable new chemical intermediates for producing perfuming ingredients. Moreover, the present invention comprises also a process for producing compound of formula (I).
    Type: Application
    Filed: September 5, 2022
    Publication date: November 7, 2024
    Inventors: Oliver KNOPFF, Nicolas POIRIER
  • Publication number: 20240352135
    Abstract: The invention is in the field of antibodies useful in therapeutic and diagnostics applications targeting CD127, the alpha chain of the IL7 receptor, and provides in particular humanized monoclonal antibodies against CD127, particularly human CD127, therapeutic uses thereof, and diagnostics applications.
    Type: Application
    Filed: March 9, 2024
    Publication date: October 24, 2024
    Inventors: Nicolas POIRIER, Caroline MARY, Bernard VANHOVE, Virginie THEPENIER
  • Publication number: 20240309096
    Abstract: The invention pertains to the field of immunotherapy. The present invention provides new specific humanized anti-CLEC-1A antibodies, antigen-binding fragments thereof and mimetics thereof, in particular antibodies. The compounds of the invention are able to specifically binds to CLEC-1A receptor and antagonize the binding of CLEC-1A to its endogenous ligand(s). The use of the compounds of the invention may be useful for treating deleterious conditions.
    Type: Application
    Filed: June 8, 2022
    Publication date: September 19, 2024
    Inventors: Sabrina PENGAM, Vanessa GAUTTIER, Caroline MARY, Nicolas POIRIER, Marion DROUIN, Elise CHIFFOLEAU
  • Patent number: 12091464
    Abstract: The present invention relates to methods for promoting T cells response. The inventors examined the expression and function of CLEC-1 in human DCs and demonstrated for the first time a cell-surface expression. They investigated its functional role following triggering on orchestration of T-cell responses. The inventors showed in vitro and in vivo with CLEC-1 deficient rats and rat CLEC-1 Fc fusion protein that disruption of CLEC-1 signalling enhances in vitro Th17 activation and in vivo enhances T cell priming and Th17 and Th1 activation. In particular, the present invention relates to CLEC-1 antagonists for promoting T cells response in a subject in need thereof.
    Type: Grant
    Filed: May 10, 2022
    Date of Patent: September 17, 2024
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE NANTES, OSE IMMUNOTHERAPEUTICS
    Inventors: Elise Chiffoleau, Geraldine Teppaz, Nicolas Poirier, Bernard Vanhove, Vanessa Gauttier
  • Publication number: 20240294659
    Abstract: The present invention pertains to the field of immunotherapy. More specifically, the present invention provides a method for differentiating myeloid-derived suppressor cells (MDSC) into non suppressive cells, by administering a compound blocking the interaction between SIRP? and CD47 to a patient in need thereof, in order to reduce MDSC-induced immunodepression and consequently allow appropriate immune responses in cancers, infectious diseases, vaccination, trauma, autoimmune diseases, chronic inflammatory diseases and transplantation.
    Type: Application
    Filed: April 25, 2024
    Publication date: September 5, 2024
    Inventors: Nicolas Poirier, Bernard Vanhove
  • Patent number: 12077820
    Abstract: The invention relates to the identification of biomarkers of the response status of a patient for a treatment with anti-TN-Falpha agents, for treatment with anti-?4?7 agents or with both anti-TNFalpha agent and anti-?4?7 agents and to their use in assessing such status, in particular for assessing nonresponsive status for a treatment with anti-TNFalpha agents or respectively with anti-?4?7 agent in human patients suffering from inflammatory condition or disease, in particular Inflammatory Bowel Disease (IBD), in particular Ulcerative Colitis or Crohn's disease.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: September 3, 2024
    Assignees: OSE IMMUNOTHERAPEUTICS, CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
    Inventors: Nicolas Poirier, Richard Danger